421 related articles for article (PubMed ID: 33829299)
1. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA
Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO).
Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Niederwieser D; Dölken G
Ann Hematol; 2014 Sep; 93(9):1587-97. PubMed ID: 24782119
[TBL] [Abstract][Full Text] [Related]
3. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
[TBL] [Abstract][Full Text] [Related]
4. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL.
Sohn SK; Baek JH; Kim DH; Jung JT; Kwak DS; Park SH; Suh JS; Lee KB
Am J Hematol; 2000 Sep; 65(1):75-80. PubMed ID: 10936869
[TBL] [Abstract][Full Text] [Related]
5. A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.
Stewart DA; Duan Q; Carlson L; Russell JA; Bahlis NJ; Duggan P; Hasegawa W; Voralia M
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):475-82. PubMed ID: 21831743
[TBL] [Abstract][Full Text] [Related]
6. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.
Robinson S; Dreger P; Caballero D; Corradini P; Geisler C; Ghielmini M; Le Gouill S; Kimby E; Rule S; Vitolo U; Dreyling M; Hermine O;
Leukemia; 2015 Feb; 29(2):464-73. PubMed ID: 25034148
[TBL] [Abstract][Full Text] [Related]
7. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
Dietrich S; Boumendil A; Finel H; Avivi I; Volin L; Cornelissen J; Jarosinska RJ; Schmid C; Finke J; Stevens WB; Schouten HC; Kaufmann M; Sebban C; Trneny M; Kobbe G; Fornecker LM; Schetelig J; Kanfer E; Heinicke T; Pfreundschuh M; Diez-Martin JL; Bordessoule D; Robinson S; Dreger P
Ann Oncol; 2014 May; 25(5):1053-8. PubMed ID: 24585719
[TBL] [Abstract][Full Text] [Related]
8. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
Chen YB; Li S; Fisher DC; Driscoll J; Del Rio C; Abramson J; Armand P; Barnes J; Brown J; Cutler C; El-Jawahri A; Ho VT; Hochberg E; McAfee S; Takvorian R; Spitzer TR; Antin JH; Soiffer R; Jacobsen E
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1583-8. PubMed ID: 26009261
[TBL] [Abstract][Full Text] [Related]
9. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M;
Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086
[TBL] [Abstract][Full Text] [Related]
10. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
11. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.
Lefrère F; Delmer A; Suzan F; Levy V; Belanger C; Djabarri M; Arnulf B; Damaj G; Maillard N; Ribrag V; Janvier M; Sebban C; Casasnovas RO; Bouabdallah R; Dreyfus F; Verkarre V; Delabesse E; Valensi F; McIntyre E; Brousse N; Varet B; Hermine O
Leukemia; 2002 Apr; 16(4):587-93. PubMed ID: 11960337
[TBL] [Abstract][Full Text] [Related]
12. Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation.
Shanbhag S; Smith MR; Emmons RV
Stem Cells Cloning; 2010 Jul; 3():93-102. PubMed ID: 24198514
[TBL] [Abstract][Full Text] [Related]
13. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
Hermine O; Jiang L; Walewski J; Bosly A; Thieblemont C; Szymczyk M; Pott C; Salles G; Feugier P; Hübel K; Haioun C; Casasnovas RO; Schmidt C; Bouabdallah K; Ribrag V; Kanz L; Dürig J; Metzner B; Sibon D; Cheminant M; Burroni B; Klapper W; Hiddemann W; Unterhalt M; Hoster E; Dreyling M;
J Clin Oncol; 2023 Jan; 41(3):479-484. PubMed ID: 36469833
[No Abstract] [Full Text] [Related]
14. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
[TBL] [Abstract][Full Text] [Related]
15. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.
Tam CS; Khouri IF
Leuk Lymphoma; 2009 Aug; 50(8):1239-48. PubMed ID: 19562639
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.
Rule S; Cook G; Russell NH; Hunter A; Robinson S; Morley N; Sureda A; Patrick P; Clifton-Hadley L; Adedayo T; Kirkwood A; Peggs KS
Br J Haematol; 2019 Mar; 184(6):999-1005. PubMed ID: 30560573
[TBL] [Abstract][Full Text] [Related]
17. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
Ogura M; Yamamoto K; Morishima Y; Wakabayashi M; Tobinai K; Ando K; Uike N; Kurosawa M; Gomyo H; Taniwaki M; Nosaka K; Tsukamoto N; Shimoyama T; Fukuhara N; Yakushijin Y; Ohnishi K; Miyazaki K; Sawada K; Takayama N; Hanamura I; Nagai H; Kobayashi H; Usuki K; Kobayashi N; Ohyashiki K; Utsumi T; Kumagai K; Maruyama D; Ohmachi K; Matsuno Y; Nakamura S; Hotta T; Tsukasaki K;
Cancer Sci; 2018 Sep; 109(9):2830-2840. PubMed ID: 29957865
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.
Drach J; Huang H; Samoilova O; Belch A; Farber C; Bosly A; Novak J; Zaucha J; Dascalescu A; Bunworasate U; Masliak Z; Vilchevskaya K; Robak T; Pei L; Rooney B; van de Velde H; Cavalli F
Leuk Lymphoma; 2018 Apr; 59(4):896-903. PubMed ID: 29338540
[TBL] [Abstract][Full Text] [Related]
20. The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma.
Ying ZT; Zheng W; Wang XP; Xie Y; Tu MF; Lin NJ; Ping LY; Liu WP; Deng LJ; Zhang C; Zhu J; Song YQ
Chin J Cancer; 2012 Jul; 31(7):348-53. PubMed ID: 22704490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
